Health

Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine

STOCKHOLM, April 1, 2021 /PRNewswire/ -- Iconovo AB (publ), a company developing complete inhalation products for a global market, today announced that it has signed an agreement with the immunotherapy company Immune System Regulation AB (ISR), an affiliate to ISR Immune System Regulation Holding...

2021-04-01 03:19 1197

VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled

SHANGHAI, March 31, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully completed its recruiting target of 150 subjects for the Phase-III registration clinical trial inChina to evalu...

2021-03-31 23:53 1809

Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate

SUZHOU, China and ROCKVILLE, Md., March 31, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full ...

2021-03-31 23:27 2243

Five New 'Key Opinion Leaders' Appointed to Blinkcns Scientific Advisory Board

Dr. Angelo Antonini, Dr. Matteo Bologna, Roy Jones, Dr. Fidias Leon-Sarmiento, and Dr.Fabrizio Stocchi, will help guide company as they advance central nervous system research CHARLESTON, South Carolina, March 31, 2021 /PRNewswire/ -- Blinkcns, Inc, a biotechnology company pioneering blink refle...

2021-03-31 21:00 826

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-03-31 20:45 3268

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-31 20:30 1764

Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enr...

2021-03-31 20:00 9844

BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T

VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request ...

2021-03-31 20:00 2718

Universal Medical Announced its 2020 Annual Results

2020 ANNUAL RESULTS HIGHLIGHTS * The revenue amounted to approximately RMB8,521.2 million, representing an increase of 25.0% as compared with that of approximatelyRMB6,815.6 million for 2019. * The profit before tax amounted to approximately RMB2,365.0 million, representing an increase of 6....

2021-03-31 19:55 2396

AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market

SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...

2021-03-31 19:30 2092

Future Health: Innovative Health Around the World

LONDON, March 31, 2021 /PRNewswire/ -- It started with the UK but the renowned organisers of Future Health Innovation have recently announced the launch of a full series of digital events - the Health Week Series. Concentrating on key markets around the world, there will be a Summer and Autumn ev...

2021-03-31 18:36 1849

CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

SUZHOU, China, March 31, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration ...

2021-03-31 18:20 6557

LightAir IonFlow air purifier effectively reduces the infectivity of viruses that mimic coronaviruses

STOCKHOLM, March 31, 2021 /PRNewswire/ -- The IrsiCaixa AIDS Research Institute has carried out tests and today presented a report which shows that LightAir's technology IonFlow neutralizes viruses that mimic SARS-CoV-1 and SARS-CoV-2 in drop form on surfaces. This evidence can now be added to a ...

2021-03-31 17:58 1218

20th Edition of Beautyexpo & 16th Edition of Cosmobeauté Malaysia Are Debuting The First Beauty Hybrid Event In Malaysia

KUALA LUMPUR, Malaysia, March 31, 2021 /PRNewswire/ -- The 20th Edition of beautyexpo and 16th Edition of Cosmobeauté Malaysia organised by Informa Markets will be held inhybrid edition by adding digital components to the show from 1 to4 October 2021 under one roof at Kuala Lumpur Convention Cent...

2021-03-31 12:48 3145

Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)

* BLA submission to the U.S. FDA follows successful conclusion of Evive's Global Phase III Clinical Trial for chemotherapy-induced neutropenia in breast cancer patients. * Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a complet...

2021-03-31 11:26 2442

Cigna Study Shows Uncertainty about the Future as Leading Cause of Stress

HONG KONG, March 31, 2021 /PRNewswire/ -- Cigna Hong Kong today released the Hong Kong findings of the latest edition of its Cigna COVID-19 Global Impact Study. As part of Cigna's annual 360 Well-Being Survey, this research is the fourth in a series of studies to better understand the impact of t...

2021-03-31 11:09 3175

Fosun International Issues a Letter to Shareholders

HONG KONG, March 31, 2021 /PRNewswire/ -- Fosun International (00656) today released a letter to shareholders, the full text of which is provided below. Dear distinguished shareholders, In 2020, the raging pandemic of novel coronavirus pneumonia ("COVID-19") imposed tremendous challenge to...

2021-03-31 10:57 4139

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression

SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-31 10:27 3563

Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...

2021-03-31 10:00 4678

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...

2021-03-31 09:11 3098
1 ... 635636637638639640641 ... 858